| Name | Title | Contact Details |
|---|
Avid Medical Inc is a Toano, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Twenty years ago, we pioneered the world`s first clear aligners. Since then, we have continuously innovated with new products and technologies that are revolutionizing treatments for doctors and their patients. Invisalign clear aligners and the iTero Intraoral scanner help dental professionals achieve the clinical results they expect and deliver effective, advanced dental options to their patients.
Noesis Health is a Lynn Haven, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vitale Group is a Lutherville Timonium, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NeuroOne Medical Technologies Incorporated (Ticker: NMTC) is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, initially targeting epilepsy. Today, our attention is on the development and commercialization of patented thin-film, cortical electrode technology for intracranial electroencephalography (iEEG) and depth electrodes for stereoelectroencephalography (sEEG) recording of brain activity. The products currently available in these categories have significant limitations such as low recording resolution and high risk of infection. NeuroOne believes our technology can address these unmet needs upon initial commercialization with pipeline technology to advance the field by enabling minimally invasive techniques and all-in-one diagnostic and therapeutic options. While our initial focus is Epilepsy, future applications in Parkinson`s disease, Essential tremors, and Dystonia are within sight. NeuroOne technologies will be presented to a well-defined market, eager for the advancement they bring. There are 188 hospital centers licensed to perform epilepsy surgical procedures in the U.S. The current addressable market opportunity for is approximately $525.6 million. As more patients choose the minimally invasive procedures made available by NeuroOne technology, the future opportunity is estimated to be approximately $14.9 billion with full market penetration.